Chao Family Comprehensive Cancer Center

Orange, California 92868-3298

3 studies enrolling now · 159 studies all time

What they study most

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, Accessory; Breast Tissue, Adenocarcinoma of the Prostate, Adenomatous Polyp, Adrenocortical Carcinoma, Adult Primary Liver Cancer, Advanced Clear Cell Renal Cell Carcinoma, Advanced or Metastatic Solid Tumors, Bladder Cancer, Brain Tumor, Brain and Central Nervous System Tumors, Breast Cancer

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study — Recruiting now
• Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities — Recruiting now
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab — Recruiting now
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib — Completed
• A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Completed
• A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation — Running, not enrolling
• A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors — Completed
• Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors — Completed
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) — Completed
• A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) — Completed
• A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations — Completed
• Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting — Completed
• TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma — APPROVED_FOR_MARKETING
• Trial of Aspirin and Arginine Restriction in Colorectal Cancer — Completed
• Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma — Completed
• Combination Chemotherapy in Treating Women With Breast Cancer — Completed
• Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID) — Completed
• Development of a Quantitative Tissue Optical Index of Breast Density For Prediction of Hormone Therapy Response — Withdrawn before enrolling
• Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy — Completed
• Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women — Completed
• Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer — Completed
• Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma — Completed
• Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients — Completed
• A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma — Stopped early
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) — Stopped early
• Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer — Completed
• Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed — Completed
• Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer — Completed
• Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma — Completed
• Neoadjuvant Treatment of Breast Cancer — Completed
• Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer — Completed
• Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma — Stopped early
• Cellular Immune Augmentation in Colon and Rectal Cancer — Completed
• Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection — Completed
• Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma — Completed
• Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma — Completed
• Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma — Completed
• Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer — Stopped early
• Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer — Stopped early
• Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus — Stopped early
• Green Tea Extract in Treating Patients With Actinic Keratosis — Stopped early
• Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer — Completed
• Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma — Completed
• Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma — Stopped early
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed
• Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab — Stopped early
• LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis — Completed
• Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer — Stopped early